This week the world lost a friend, colleague and advocate for IBD patients. For decades, Patrick McLean dedicated his talents to advancing research into anti-mycobacterial treatment solutions for chronic immune diseases such as Crohn’s and multiple sclerosis. He had great compassion for patients, and exemplified the best of humanity. Our community was blessed to have known him, and he leaves a legacy that will ripple throughout time.

Human Para’s second research, which sought to detect MAP in blinded blood samples from Crohn’s and control pediatric subjects, has now concluded. Read on to see the results.

Human Paratuberculosis Foundation is dedicated to providing the latest research and information about the role of Mycobacterium avium subsp. paratuberculosis (MAP) in chronic immune conditions such as Crohn’s disease, multiple sclerosis, Type 1 diabetes, ulcerative colitis, sarcoidosis, Parkinson’s disease, rheumatoid arthritis, lupus and more. Our goal is to assist researchers, health care professionals and patients around the world. We are grateful for the support of our community and look forward to taking this journey together. Enjoy the latest edition of our quarterly newsletter!

What is the Susceptibility of MAP Strains to Antibiotic Combinations? Human Para, in conjunction with the Keating Family Foundation, is proud to announce their commitment to support a new research partnership between Johns Hopkins Medicine and Otakaro Pathways. Read on to learn more about our latest project!

Human Para is excited to share the preprint article detailing the results of our landmark MAP/Crohn’s disease testing study that began in 2018. Viable MAP was detected in a significant number of study subjects across all groups. A more detailed analysis is available on the HumanPara.org website. Thank you to all of the participants and their families, the researchers who volunteered their time for this study, and the donors who made funding this critical research a reality.